The virus is named for its distinctive spike proteins that protrude from its envelope, creating a crown-like appearance. SARS-CoV-2 possesses a helical capsid containing single-stranded RNA as its genetic material. The capsid is formed via phosphorylation of the nucleocapsid (N) protein. The structural proteins in the envelope include spike (S) glycoprotein, hemagglutinin esterase (HE), membrane (M) protein, and envelope (E) protein (Figure 3 )17.

Figure 3

In typical coronaviruses (CoVs), the S protein of SARS-CoV-2 facilitates host cell receptor recognition and initiates the viral infection cycle. The S2 subunit comprises the fusion peptide, heptapeptide repeat sequences (HR1 and HR2), a transmembrane domain, and cytoplasmic domains, arranged systematically. These components are crucial for viral fusion and entry into the host cell, making them an attractive drug target13, 18. The fusion peptide is an oligopeptide composed of water-repelling glycine or alanine residues that disrupt the lipid bilayer of the host cell’s plasma membrane, aiding in membrane fusion. Meanwhile, HR1 and HR2 facilitate viral fusion and entry by forming the six-helical bundle structure. They are part of a repetitive HPPHCPC heptapeptide sequence, where H, P, and C stand for hydrophobic, polar (hydrophilic), and charged residues, respectively19. As the receptor-binding domain (RBD) binds to angiotensin-converting enzyme 2 (ACE2), the S2 subunit undergoes a conformational change due to the fusion peptide attaching to the target cell membrane, exposing the pre-hairpin structure of the HR1 trimer (Figure 3 ). This trimer contains three highly conserved hydrophobic furrows, which then become exposed.

Upon entering the host, the virus binds the transmembrane serine protease 2 (TMPRSS2), leading to the activation of the S protein and formation of the RBD via proteolytic cleavage. The RBD can now interact with the ACE2 receptor, facilitating viral fusion with the membrane and allowing replication within the host.

The hydrophobic furrows formed by the stiff helix and a flexible loop of the HR2 domain facilitate interaction with the HR1 domain. The S protein comprises two structural domains: the core subdomain and the external subdomain. The core is highly conserved (Figure 3 ), containing five β strands arranged in an antiparallel manner, with a disulfide bond linking two of these strands. Meanwhile, the external subdomain is characterized by a loop stabilized through a disulfide bond13, 20.

Since the S1 units are highly variable, the conserved sequence of the S2 subunits offers tremendous therapeutic potential for antiviral drug targets. The HR1 and HR2 heptapeptide repeats interact with peptidomimetics derived from these domains, effectively blocking viral entry by disrupting the six-helix bundle (6HB) structure mainly responsible for membrane fusion. Thus, peptidomimetics may be explored for targeted SARS-CoV-2 therapy18.

Furthermore, in addition to the ACE2 receptor, the virus exploits alternative routes for viral entry into host cells, including L-SIGN, DC-SIGN, TIM1, AXL, C-type lectins, CD147, and glucose-regulated protein (GRP78)19. GRP78 is a chaperone involved in protein homeostasis under normal conditions, but in stressful conditions, such as old age, diabetes, and obesity, it is overexpressed on the cellular membrane and facilitates viral entry, inflammation, apoptosis, and cell signaling7, 9.

The genome of SARS-CoV-2 comprises about ten open reading frames (ORFs), including ORF1a and ORF1b. ORF1a and ORF1b encode a total of 16 non-structural proteins (NSPs), namely, nsp1–16, while six accessory proteins are also present. The genome also contains regions that encode for specific viral proteins, including Plpro, 3CLPro, RdRp, Hel, and S, which include the N-terminal domain (NTD), RBD, SD1, SD2, FL, HR1, HR2, and TM. The dotted line in Figure 4 indicates the furin cleavage sites of the S1/S2 and S2' and TMPRSS221, 22, 23, 24.

Figure 4

The genome of SARS-CoV-2 consists of positive-sense RNA with a 5’ cap and a 3’ poly-A tail, characterized by a low G+C content of approximately 38%. The virus encodes N, E, M, and S structural proteins, which serve as major virulence factors25. SARS-CoV-2 contains the six ORFs that are common to all CoVs. At the 5′ end, two overlapping ORFs, ORF1a and ORF1b, are translated from the genome to generate the continuous polypeptide pp1ab.

About two-thirds of the positive-strand genome is constituted by ORF1a and ORF1b. ORF1a translates into pp1a, which then generates polyproteins pp1a and pp1ab, collectively giving rise to 16 NSPs. NSP3, a papain-like protease (PLpro), facilitates the polypeptide cleavage. NSP5 (Mpro/3CLpro), the primary protease, results in the formation of various non-structural proteins as depicted in Figure 4 23, 25. Mpro is a significant protease that undertakes the initial and most crucial viral polyprotein cleavages at distinct sites, producing functional proteins. Thus, inhibition of Mpro could be a viable anti-CoV drug target26. The polyprotein pp1a undergoes enzymatic cleavage to yield 11 NSPs, while pp1ab forms 15 NSPs. Further, six auxiliary proteins are encoded by ORFs 3a, 6, 7a, 8, and 10 (Figure 4 )13, 23.

Nsp12 functions as an RdRp, serving as a fundamental functional unit in viral replication and transcription mechanisms. Essential cofactors nsp7 and nsp8 facilitate the binding of RdRp to its template RNA strand and enhance its enzymatic activity. It is essential for replication and transcription machinery of SARS-CoV-2. Structurally, it exhibits a right hand-like shape and possesses domains such as the N-terminal nidovirus RdRp-associated nucleotidyl transferase (NiRAN), the C-terminal region, and an interface domain. This enzyme is a primary focus for many antiviral drugs like remdesivir27, 28.

The 3’ ORF, encompassing the remaining genome (including genes encoding for the remaining structural and auxiliary proteins), is formed via a replication-transcription complex (RTC)22, 23. The viral 3’ untranslated region (UTR) within the genome harbors the initial binding site of the RTC and multiple cis-acting regulatory elements crucial for the viral genome transcription and replication29.

Studies have indicated that beta-coronaviruses adjust the length of the coronaviral poly-A tail during the infection of human rectum tumor 18 (HRT18) cells. Initially ranging from approximately 26–45 nucleotides, the poly-A tail of the viral RNA reaches a peak of about 65 nucleotides between 6–10 hours post-infection. Subsequently, this length gradually decreases to 30–45 nucleotides after 10 hours. Additionally, it has been determined that the effectiveness of virus translation is linked to the length of the coronaviral poly-A tail30. ORF3 hinders host interferon (IFN) signaling and triggers the inflammasome and apoptosis of the host cell. ORF7a also inhibits the host protein translation and promotes pro-inflammatory signaling. ORF N inhibits the RNA sensing mechanisms and STAT1/2, and ORF M suppresses the RIG-1, MDA5, and TRAF-3–TANK–TBK1/IKK epsilon complex31.

Table 1

Name of Strain	Mutation	Origin of Mutation	Reference
Gamma	P.1	January 2020 in Japan/Brazil	12, 24, 32
Zeta	P.2	April 2020 in Brazil
Lambda	C.37	August 2020 in Peru
Iota	B.1.526	November 2020 in New York
Alpha	B.1.1.7	December 2020 in USA
Beta	B.1.351	December 2020 in South Africa
Eta	B.1.525	December 2020 in UK & Nigeria
Theta	P.3	February 2021 in Philippines
Epsilon	B.1.427	March 2021 in USA
Kapa	B.1.617.1	April 2021 in India
Delta	B.1.617.2	May 2021in India
Mu	B.1.621	August 2021 in Columbia
Omicron	B.1.1.529	November 2021 in South Africa

Figure 5

The viral S proteins are major virulence factors, and any mutation in the RBD can lead to a new variant with varying virulence levels. Bioinformatics analysis revealed the most probable mutation sites across various SARS-CoV-2 strains (Table 1 ). These mutations are classified based on how they affect disease severity, diagnosis, transmission, and therapies, and can be categorized into variants of concern (B.1.1.7, B.1.351, B.1.427, B.1.429, P.1), variants of high consequence; and variants of interest33. The evolution of S protein in the virus has resulted in numerous sub-lineages of Omicron (B.1.1.529), namely, BA.1, BA.2, BA.3, BA.4, and BA.5, as well as additional sub-lineages BQ.1, BQ.11, BF.7, BA.2.75, and XBB. The BF.7 variation, also referred to as BA.2.75.2, is the most infectious, featuring a shortened latent period. The symptoms associated with BF.7 infection resemble those of other Omicron subvariants. The fundamental reproduction number of BF.7 is 10 to 18.6, which is much higher than the BA.1 Omicron variation, which is just 5.08. The enhanced transmission rate is due to novel mutations in the S protein R346T found on the RBD, which enhance its ability to evade neutralizing antibodies generated by vaccination or past infections.

Consequently, infections caused by BF.7 variant have resulted in significant disease in people with weakened immune systems34. The high transmissibility of the coronavirus and its rapid pandemic spread may be attributed to RNA as a genetic material prone to mutations and the airborne nature of the virus.

The Receptor Binding Domain: The RBD consists of a core made up of beta sheets with antiparallel strands covered with alpha helices and a loop called the receptor binding motif, which wraps around the ACE-2 receptor, thereby initiating direct contact35, 36. The S2 subunit is a transmembrane domain containing fusion peptides involved in the fusion of viral and cellular membranes through conformational modifications32, 37. The RBD also contains three of the missense mutations that are otherwise present in the non-structural and structural proteins, with the exception of the E protein.

High Infectivity of SARS-CoV-2: The virus spike proteins in SARS-CoV-2 show a notably higher infection rate compared to other SARS-CoVs, primarily due to an additional furin cleavage site containing multi-basic amino acids at the junction between the S1 and S2 subunits of the S protein38. The S1 unit is located on the membrane surface and contains the RBD, which specifically binds to the ACE-2 receptor in human hosts, thereby determining the specificity and pathogenicity (37). ACE-2 receptors are widely expressed on epithelial cells of the upper respiratory tract and endothelial cells of arteries, veins, immune cells, and cerebral neurons; this demonstrates the wide range of infectivity of the virus. Thus, in children, the tubular epithelial cells of the kidney, intestinal mucosal cells, and renal epithelial cells become potent targets for viral infection39.

Two prominent strains of the SARS-CoV-2 virus were discovered. According to Tang et al., these strains were found by analyzing 103 different virus genome sequences. Less than 30% of these were of type S, while 70% were of type L. The Wuhan, China outbreak began with a high prevalence of the L type; however, this has since declined. Type L is considered to be more aggressive and contagious than type S40.

Upon viral entry in the host cell, it adopts two strategies: first, the E proteins continue the cycle by contributing to viral lysis and ultimately releasing the viral genome into the cell39. The entry of the viral genome marks the beginning of the replication process, which is a complex process involving numerous NSPs23. During this process, multiple copies of the negative sense ss-RNA are created, which act as a template for the synthesis of the positive sense genomic RNA copies. These are further translated to form more NSPs and reverse transcription complexes or are packaged into new virion particles with the help of E proteins37, 41. The N protein aids in its genome protection and packages it into a ribonucleoprotein complex, and further suppresses the immune response of the host cell41. M protein interacts with other structural proteins to induce budding, and plays a significant role in the checkpoint system to ensure proper packaging of the virion particle (Figure 5 )26.

The S protein trimer protrudes from the viral envelope and enables specific binding to cellular receptors, i.e., ACE2, to promote viral entry and fusion. Upon entry, the viral RNA is translated into two large ORFs. These ORFs are subsequently processed into NSPs that assemble into the viral replication and transcription complex. This complex generates viral replication organelles, including characteristic double-membrane vesicles and convoluted membranes. These structures provide a protected environment for genomic RNA replication and sub genomic mRNA transcription. Newly synthesized structural proteins are translocated into the endoplasmic reticulum membrane, where they interact with the newly produced genomic RNA before budding into secretory vesicles. Ultimately, the mature virions are expelled from the infected cell through exocytosis.

Secondly, transcription in CoVs appears more complicated compared to other positive-sense viruses, leading to premature termination and internal initiation. Apart from replication, in transcription there is a peculiar discontinuous step for sub-genomic messenger RNA (sgmRNA) formation characteristic of Nidovirales, thus creating a nested group of sgmRNA with 5’ and 3’ co-terminal with the genome. The leader sequence confers protection from nsp-1-triggered endonucleolytic degradation of capped messenger RNA, thus leading to efficient accumulation of virus mRNA and its proteins during infection42.

The most prevalent clinical manifestations of COVID-19 infection are ageusia (loss of taste) and anosmia (loss of smell). Fungiform and surrounding papillae on the tongue contain a significant concentration of ACE2 receptors, which have been implicated in the transient modulation of taste sensitivity through the Renin-Angiotensin System (RAAS) or Renin-Angiotensin System (RAS) enzyme, potentially explaining the loss of taste49. Various sources reveal that SARS-CoV-2 can enter both the peripheral and central nervous systems, leading to detrimental neurological effects50. The virions may infiltrate the olfactory bulb via the cribriform plate of the ethmoid bone from the nose to the brain, causing ageusia and anosmia49. In vivo studies in mice have demonstrated the virus’s spread to the brain via the olfactory receptor. Hence, the altered sense of smell can occur due to the virus entering the olfactory bulb, which is responsible for smell perception, through the cribriform plate50, 51, 52.

The neurological symptoms commonly include malaise, headache, and myalgia; in severe cases, ataxia, seizures, altered consciousness, cerebrovascular disease, neuralgia, and low vision may occur35, 53. The detection of SARS-CoV-2 in cerebrospinal fluid (CSF) indicates a potential connection between the virus and the brain. Additionally, the virus is associated with elevated production of cytokines, chemokines, and other immune-modulating molecules, resulting in an intracranial cytokine storm that disrupts the blood-brain barrier49, 50, 54, 55.

Patients with cardiac and renal dysfunction are at a higher risk of COVID-associated mortality. Systematic reviews show that common cardiovascular complications in COVID-19 patients include pericarditis, myocarditis, arrhythmias, hypertension, and myocardial infarction56, 57. In cardiac patients, elevated ACE2 receptor levels serve as a protective mechanism against myocardial infarction. However, ACE2 upregulation also increases susceptibility to COVID-19 infection49, 58. Studies indicate that individuals with a history of COVID-19 have a nearly 19–28% higher risk of heart damage, 62% of hospitalized cases experience acute myocardial injuries, and about 33% of these cases result in death56. Emerging evidence suggests that people recovering from COVID-19 face a significantly increased risk of cardiovascular events, including a doubled chance of pulmonary embolism up to 4.5 months post-infection, with heightened risks of myocardial infarction and ischemic stroke persisting for several months afterward59. These heightened risks are associated with prothrombotic responses induced by the virus, viral cytotoxicity, endothelial damage, hyperimmune responses, and vasculitis. Notably, even individuals without prior heart disease have shown subclinical alterations in cardiac function post-COVID-19, suggesting possible long-term myocardial effects56, 57.

Additionally, COVID-19 has been implicated in acute kidney injury, primarily through direct viral invasion of renal cells, thrombic events, and systemic inflammation. Routine renal functions may be compromised by heightened sodium absorption, leading to elevated blood pressure35. Several laboratory results have detected the virus in urine samples. The vasculature regulating nitric oxide levels—crucial for vasodilation—is also under the control of ACE2 receptors. Increased viral load downregulates ACE2 expression on the cell surface, resulting in vascular dysfunction and inflammation. Histopathological analyses often reveal acute tubular necrosis and glomerular injury. In one retrospective cohort study of 372 patients, those with mixed etiologies of acute kidney injury exhibited the highest mortality rates (90.5%) and required dialysis (85.1%). The study emphasizes that the severity and outcome of acute kidney injury in COVID-19 patients (OR= 4.8, CI= 1.7–13.4, p = 0.003) are closely tied to the underlying pathophysiological mechanisms. These findings underscore the critical need for ongoing monitoring of cardiovascular and renal functions in COVID-19 patients, even months after the acute infection phase60, 61.

Recently, additional symptoms have been documented in some patients, primarily affecting the fingers and toes, referred to as ‘COVID toes.’ These red and purple painful lesions tend to appear in later stages and could be linked to vascular complications62, 63.

Globally, diabetic patients are more susceptible to SARS and MERS infection, potentially worsening the condition. Factors contributing to this include compromised immunity due to reduced phagocytic activity, lower neutrophil function, and decreased T-cell performance. Diabetes results in elevated ACE2 receptor expression, leading to enhanced viral affinity and increased viral load64 Wijnant et al. reported higher bronchial and alveolar ACE2 expression in patients with diabetes, independent of other factors such as smoking, body mass index, comorbidities, or the usage of RAAS inhibitors. Furthermore, a direct association has been observed between blood glucose levels and alveolar ACE2 expression, which supports viral replication and may lead to potentially fatal complications due to immune system dysregulation and an exacerbated inflammatory response64, 65.

Cancer patients, being immunocompromised, are at a heightened risk for SARS-CoV-2 infection, which can increase disease severity and mortality41, 66, 67. COVID-19-positive lung cancer patients demonstrated higher inpatient mortality. Prolonged prothrombin expression and increased Troponin I sensitivity are distinct prognostic factors, helping physicians determine outcomes earlier. These patients often present atypical early symptoms and distinct imaging findings68.

Those with hematologic cancer, lung cancer, and other malignancies in advanced stages have shown a greater incidence of serious events related to SARS-CoV-2, including elevated mortality and severe symptoms69. Breast and gynecologic malignancies were found in around 50% of cancer patients examined for SARS-CoV-2 seroprevalence, suggesting an increased infection rate among females.

In a study by Cury et al., COVID-19 interactions with lung cancer were examined in A549 and Calu-3 cell lines, revealing overexpression of the cancer-linked genes BRCA1 and CENPF in small and non-small cell lung cancer, respectively, which may interact with the viral S protein and helicase (NSP13). No changes in ACE2 were observed in either cell line, but type I interferons induced ACE2 overexpression during host immune responses. The expression of ACE2 and TMPRSS2 in patients with lung adenocarcinoma and squamous cell carcinoma could suggest an increased susceptibility to infection70.

Asthma is a complex respiratory illness characterized by various inflammatory processes. Notably, standard asthma treatment involves corticosteroids and anti-asthmatic medications, which may act as potential modulators of SARS-CoV-2 infection, potentially lowering its prevalence in individuals with asthma71.

Ssentongo et al. reported an increased risk of infection and higher mortality in individuals with both COVID-19 and HIV. HIV-induced immunosuppression elevates the risk of additional comorbidities such as anemia, neutropenia, and thrombocytopenia, which can hinder COVID-19 recovery. Therefore, coinfection with COVID-19 and HIV can lead to serious outcomes if not managed effectively72.

A recent comparative study demonstrated that HIV patients with COVID-19 experience delayed recovery and lymphocytopenia, primarily attributed to reduced SARS CoV-2-specific antibody responses41.

Clinical evidence suggests that HIV-positive individuals on antiretroviral therapy exhibit reduced vulnerability to infection. However, HIV-related chronic conditions, a low CD4 (<200 cells) cell count, and uncontrolled HIV viremia have been associated with worsened COVID-19 severity and increased mortality73.

Viral infections can alter the mother’s innate immune response during pregnancy74. In the first trimester, increased ACE2 receptor expression is observed on villous cytotrophoblasts, syncytiotrophoblasts, decidual cells, and the placenta, making pregnant women more susceptible and raising the possibility of vertical transmission. The blastocyst and embryos (of good quality and euploid) were also affected75.

The effect of SARS-CoV-2 on female fertility has been evaluated, showing no significant impact on ovarian reserves. Regarding the menstrual cycle, enhanced variability was noted in mild to severe infections, but these changes were reversible. Conversely, the virus may significantly affect the sexual and pubertal development, as well as fertility in young male children, by disrupting the neuroendocrine axis. In adult males, SARS-CoV-2 infection could impede spermatogenesis via considerable damage to testicular tissue, particularly impacting Sertoli cells76.

In accordance with the WHO, the persistence of COVID-19 symptoms such as muscle and joint pain, fatigue, diarrhea, abdominal pain, and cough for at least three months following recovery, and continuing for at least two months without an alternative diagnosis, is referred to as Long COVID-1977. It affects multiple organ systems, leading to chronic fatigue, respiratory issues, neurological complications, cardiovascular problems, and mental health disorders. Long COVID may arise from persistent viral reservoirs in certain organs after the primary infection, which repeatedly trigger the immune system and lead to chronic inflammation. In some patients, autoantibodies are produced, attacking their own tissues. Furthermore, microclots, impaired circulation, and vascular damage during the initial infection can reduce oxygen delivery, contributing to fatigue, organ damage, and cognitive dysfunction in Long COVID patients78.

According to a meta-analysis by Notarte et al. (2022), older age (OR 0.86, p = 0.17) may not be associated with the sequelae of Long COVID-19. However, being female (OR = 1.48, p = 0.01), having diabetes, pulmonary disease, a transplant history, and obesity may serve as risk factors79. Furthermore, a comparative meta-analysis examined post-COVID-19 cases to compare the prevalence of symptoms in both non-hospitalized and hospitalized patients. Dyspnea and fatigue (35–60%), cough (20–25%), ageusia (15–20%), joint pain (15–20%), and anosmia (10–20%) were documented, appearing in ≥60% of the cases80.

In 2022, César Fernández-de-las-Peñas et al. evaluated the prevalence of Long COVID-19 in individuals with the original viral strain and compared it to those infected by the Alpha, Omicron, and Delta variants. The original strain group experienced 50% more episodes of Long COVID-19, with fatigue being the most frequently reported symptom80.

Although COVID-19 vaccination lowers the risk of severe disease, its effect on Long COVID-19 outcomes was initially unclear. A systematic review by Notarte et al. (2022) indicated that receiving two vaccine doses correlated with reduced Long COVID-19 cases. Individuals who had at least one month between vaccination and COVID-19 infection were less likely to experience Long COVID-19 sequelae81, 82. Additional studies suggest that vaccinated individuals have a lower risk of developing Long COVID, likely due to reduced viral replication, systemic inflammation, and persistent symptoms83. Moreover, those vaccinated after infection often recover more quickly from Long COVID, as vaccination modulates the immune response and prevents the inflammation associated with prolonged symptoms. Long COVID frequently causes fatigue and neurological complications; by limiting viral spread to the nervous system, vaccination reduces these risks. Therefore, vaccines play a crucial role in decreasing disease severity and the risk of Long COVID84.

Age is among the most significant predictors of COVID-19 severity and mortality. Individuals over 60, particularly those over 70, have markedly higher hospitalization and mortality rates. Furthermore, the immune system weakens with age—a process known as immunosenescence—reducing the body’s ability to combat infections. Older adults are also more likely to have comorbidities such as heart disease, diabetes, and hypertension, which can worsen COVID-19 outcomes85.

By contrast, children and young adults typically experience milder symptoms or remain asymptomatic, though they can serve as asymptomatic carriers, transmitting the virus to more susceptible groups. Additionally, a small proportion of children develop multisystem inflammatory syndrome (MIS-C), a rare but serious COVID-19 complication86.

COVID-19 outcomes vary between males and females because of both biological and behavioral factors. Men often experience more severe disease and higher mortality rates, partly due to weaker innate and adaptive immune responses and lifestyle factors such as higher rates of smoking and alcohol consumption, which contribute to immune suppression and lung damage. Women, on the other hand, benefit from stronger immune mechanisms influenced by genetic factors and estrogen. However, pregnant individuals face heightened risks and complications from COVID-19, as previously discussed87.

Socioeconomic inequalities profoundly affect COVID-19 outcomes by influencing infection rates, healthcare access, and mortality. Individuals in low-income communities often face limited healthcare accessibility, resulting in delayed diagnoses and treatments. Lower vaccination rates also increase vulnerability to severe illness. Additionally, many frontline workers (e.g., healthcare and transportation staff) have higher exposure risks. Overcrowded living conditions and shared facilities in lower-income settings make social distancing difficult, further raising transmission risks. Poor nutrition and inadequate healthcare compound these problems88, 89.

A systematic review and meta-analysis of 72 studies—mostly from the United States—found that Black individuals experienced significantly higher COVID-19 infection (156%), hospitalization (153%), and mortality (105%) rates than white individuals90. In England, a study using a Bayesian hierarchical spatio-temporal model showed that areas with lower household incomes and higher unemployment rates had elevated COVID-19 infection rates. Moreover, a UK report found that residents of the most deprived areas were nearly twice as likely to be hospitalized for infectious diseases, including COVID-19, compared to those in wealthier regions. These findings shed light on the critical impact of socioeconomic factors on COVID-19 outcomes91.

In the United States, African American, non-Hispanic, and Indigenous populations show higher COVID-19 hospitalization and mortality rates. These disparities often result from a combination of genetic, socioeconomic, and healthcare access factors92, 93. A broad analysis of national data revealed that marginalized communities, including Black, Hispanic, and Native American individuals, faced more than double the hospitalization rate compared to White patients; age-adjusted mortality rates were also highest among these groups. Additionally, a multi-hospital study of critically ill COVID-19 patients found an increased in-hospital death risk for Hispanic patients relative to non-Hispanic patients. Such differences highlight the interplay of socioeconomic status, healthcare accessibility, and potential genetic predispositions94, 95.

Research from India and Bangladesh indicates that people with preexisting conditions such as hypertension, diabetes, and asthma are at higher risk for extended post-COVID-19 symptoms. A South Indian study reported that 39.6% of patients continued experiencing Long COVID symptoms past 16 weeks post-infection, with older age, hypertension, and asthma identified as significant predictors. In Bangladesh, more than 62% of hospitalized COVID-19 patients had comorbidities, which prolonged hospital stays and increased post-discharge complications96, 97. These findings emphasize the need for tailored healthcare strategies to address the requirements of patients with multiple health conditions.

Bharat Biotech, in collaboration with the National Institute of Virology, developed India’s first indigenous vaccine called Covaxin, which was approved on January 2, 2021, as trials conducted for the vaccine showed promising results with no major adverse effects134. Recent findings suggest effective neutralization of the B.1.1.7 SARS-CoV-2 variant. Interim analysis showed an efficacy of 80.6% for the vaccine135. It is an inactivated vaccine composed of completely inactive SARS-CoV-2 viral particles (RNA surrounded by a protein coat), transformed to prevent replication. It is one of the cheapest COVID-19 vaccines, recommended as a 2-dose regimen with a gap of 28 days between the two shots136. Studies report an increase in virus-specific IgG and other neutralizing antibodies, with a decreased rate of viral replication, after completion of the 2-dose regimen111. Covaxin is stable at 2–8°C and can thus be stored under ordinary refrigeration.

The mRNA-1273 vaccine by Moderna is the second vaccine approved by the Food and Drug Administration (FDA) after the BNT162 vaccine by Pfizer and BioNTech. Like BNT162, this is a modified mRNA vaccine encoding a prefusion-stabilized S protein from SARS-CoV-2, which is its major target. The vaccine works by triggering antibody responses, including CD4⁺ T-cell and CD8⁺ cytotoxic T-cell reactions against the viral particle137. Interim analysis conducted after Phase 3 trials reported an efficacy of about 94.5% with no major adverse conditions. However, pain at the injection site, fatigue, and headache or other mild adversities may be observed after vaccination, as in the case of older adults134. The vaccination process follows a two-dose regimen with a gap of 28 days between doses, and unlike the BNT162 vaccine by Pfizer, Moderna’s vaccine can be stored at about -20°C138. As per the reports, the vaccine is best suited for people 18 years or older, providing immunogenicity that lasts for at least 119 days from the first dose139. The Moderna vaccine also produced significant results for pregnant individuals, as a study suggested an equal probability of adverse pregnancies and neonatal outcomes in vaccinated people and those not vaccinated, although consultation regarding the vaccine is a must for pregnant women140.

In response to the evolving viral landscape, updated mRNA vaccines targeting the XBB.1.5 lineage have been developed, and they also demonstrated an increase in neutralizing antibodies against BA.2.86 post-vaccination141. Similarly, Pfizer has also updated its vaccine, showing enhanced immune responses against JN.1 subvariants, including KP.2 and KP.3142. These findings suggest that while the updated boosters improve protection, the degree of efficacy varies among different strains.

BNT162 is the first COVID-19 vaccine approved by the US FDA showing an efficacy of 95% as determined after Phase 3 clinical trial results134. The occurrence of major adverse events was found to be lower in comparison with Moderna’s vaccine, and thus, the Pfizer vaccine was approved for people 16 years and above. It also provides immunogenicity for at least 119 days after the first dose; however, it is much more temperature sensitive than the Moderna vaccine and is preferably stored at -75°C139. The vaccine relies on nucleoside-modified RNA that works against the S protein of the SARS-CoV-2 virus, which is its major virulence factor. This immunization prompts the body to make an antibody response to neutralize the infection, which is reliant upon the S protein for passage through the ACE2 receptors on type 2 alveolar cells. As of 16 May 2021, 85 countries had approved the Pfizer vaccine137.

AZD1222 COVID-19 vaccine developed by the Oxford University and the British-Swedish pharmaceutical company AstraZeneca is an adenoviral vaccine previously called ChAdOx1. It is a non-replicating chimpanzee adenoviral vaccine, which is also manufactured under the name Covishield in India by the Serum Institute of India using the same formulations137. It was approved by the UK on Dec, 30, 2020, and by India on Jan. 2, 2021. The vaccine works by inducing humoral and cellular responses against the SARS-CoV-2 virus and can be easily stored at 2–8°C134. As per an interim analysis, the vaccine showed an efficacy of about 70.4% after completion of its two-dose regimen with a gap of about 4–12 weeks and was thus recommended for emergency usage in the UK for people 18 years or older.

There is no single cure for long COVID, and treatment is symptomatic and multidisciplinary. Lifestyle and holistic approaches have been proven beneficial. A balanced diet, adaptively graded exercise, meditation, proper sleep, and consumption of probiotics may assist in ameliorating the symptoms of long COVID. Low doses of naltrexone show a reduction in inflammation and neurological conditions. Serotonin and serotonin-norepinephrine reuptake inhibitors may also help in some cases. Anticoagulants can aid in dissolving microclots, while studies with Remdesivir, Paxlovid, corticosteroids, and monoclonal antibodies are ongoing for long COVID143.

Further, some of the therapeutic developments are underway, such as the RECOVER-VITAL trial investigating whether extended courses of Paxlovid (nirmatrelvir, ritonavir)—an antiviral approved for acute COVID-19—can alleviate long COVID symptoms. Preliminary data from a study involving 13 long COVID patients showed mixed outcomes (9 showed some improvement, 5 reported lasting effects, while 4 saw no improvement). The REVERSE-lc and ADDRESS-LC trials are testing immunomodulatory drugs like baricitinib and bezisterim, aiming to target the immune system rather than the virus. These trials will address the complex immune dysfunction observed in long COVID patients. Meanwhile, RECOVER-NEURO is exploring brain training and stimulation interventions, such as web-based training and a home-based device for transcranial direct stimulation, to address cognitive dysfunction associated with long COVID.